COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)

Similar documents
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division

What is this document and who is it for?

Rotavirus Vaccine: Supply & Demand Update. UNICEF Supply Division

HPV Vaccine Lessons Learned & New Ways Forward

TT Procured by UNICEF

Gavi s strategic framework 22 June 2016

Annex 2 A. Regional profile: West Africa

Aboubacar Kampo Chief of Health UNICEF Nigeria

Eligibility List 2018

EXPLANATION OF INDICATORS CHOSEN FOR THE 2017 ANNUAL SUN MOVEMENT PROGRESS REPORT

Update from GAVI Aurelia Nguyen

Malaria Funding. Richard W. Steketee MACEPA, PATH. April World Malaria Day 2010, Seattle WA

Sourcing of ARVs & HIV diagnostics. Procurement for Impact P4i

Prioritizing Emergency Polio Eradication Activities

Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries

VIEW-hub Report: Global Vaccine Introduction and Implementation

Review of decisions Debbie Adams

AIDS in Africa. An Update. Basil Reekie

Health systems and HIV: advocacy. Interagency Coalition on AIDS and Development

Gavi Unicef Vaccine Industry Consultation. Dominic Hein Market Shaping / Gavi. October Reach every child

Supplementary appendix

Private Sector Opportunities to Support Family Planning and Access to Reproductive Health Services

Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York

Global Fund Results Fact Sheet Mid-2011

Global reductions in measles mortality and the risk of measles resurgence

Global Fund ARV Fact Sheet 1 st June, 2009

PROGRESS REPORT ON THE ROAD MAP FOR ACCELERATING THE ATTAINMENT OF THE MILLENNIUM DEVELOPMENT GOALS RELATED TO MATERNAL AND NEWBORN HEALTH IN AFRICA

ONLINE APPENDIX. The Lives Saved Tool (LiST) (Version 4.2 Beta 7) was used to. project the number of child deaths that would be averted between

Closing the loop: translating evidence into enhanced strategies to reduce maternal mortality

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

IMMUNIZATION VACCINES & EMERGENCIES

BCG. and your baby. Immunisation. Protecting babies against TB. the safest way to protect your child

Comparative Analyses of Adolescent Nutrition Indicators

GAVI Alliance Board Meeting, 30 November 1 December 2010 Updates

Scaling Up Nutrition Action for Africa

1) SO1: We would like to suggest that the indicator used to measure vaccine hesitancy be DTP 1 to measles first dose dropout.

IMMUNIZATION & VACCINE PREVENTABLE DISEASES

Funding for AIDS: The World Bank s Role. Yolanda Tayler, WB Bi-regional Workshop for the Procurement of ARVs Phnom Penh, Cambodia

Progress has been made with respect to health conditions.

Financing malaria control

Global Fund Mid-2013 Results

Rotavirus vaccines: Issues not fully addressed in efficacy trials

PROGRESS REPORT ON CHILD SURVIVAL: A STRATEGY FOR THE AFRICAN REGION. Information Document CONTENTS

The Promise of Introducing Rubella Containing Vaccines on the Impact of Rubella and Measles Control

Fighting Harder and Smarter Against Malaria. Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010

GABON. Neglected tropical disease treatment report profile for mass treatment of NTDs

What is Treatment Optimisation (TO)

UNAIDS 2013 AIDS by the numbers

Africa s slow fertility transition

JOINT TB AND HIV PROGRAMMING

מדינת ישראל. Tourist Visa Table

Vaccine Pricing: Gavi Transitioning Countries

Impact Dashboard - October 2014

1. Consent for Treatment This form must be completed in order to receive healthcare services in the campus clinic.

APPENDIX II - TABLE 2.3 ANTI-TOBACCO MASS MEDIA CAMPAIGNS

Prioritising vaccine support the GAVI perspective

Analysis of Immunization Financing Indicators from the WHO-UNICEF Joint Reporting Form (JRF),

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

Update on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012

Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division

Pharmacovigilance BMGF Perspective. Raj Long Bill & Melinda Gates Foundation

Impact Dashboard - August 2014

Update from the GAVI Alliance Seth Berkley, MD Chief Executive Officer

Yellow fever Vaccine investment strategy

מדינת ישראל. Tourist Visa Table. Tourist visa exemption is applied to national and official passports only, and not to other travel documents.

CEO Board report Seth Berkley MD CEO

Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative

Development of the Polio Eradication and Endgame Strategic plan

IX. IMPROVING MATERNAL HEALTH: THE NEED TO FOCUS ON REACHING THE POOR. Eduard Bos The World Bank

Taking ownership and driving progress:

Disparities in access: renewed focus on the underserved. Rick Johnston, WHO UNC Water and Health, Chapel Hill 13 October, 2014

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

O c t o b e r 1 0,

Financing the HIV response in sub- Saharan Africa from domestic sources: moving beyond a normative approach

Presentation title at-a-glance info (in slide master) Introduction to the Gavi CSO Platforms Project

Outcomes of the Global Consultation Interim diagnostic algorithms and Operational considerations

Tipping the dependency

D TA companion & Scorecard. to the UNICEF Gender Action Plan. May 2016

GAVI 5.0 THE ALLIANCE S STRATEGY

THE CARE WE PROMISE FACTS AND FIGURES 2017

Impact of Pathology Implementation Strategies in Sub Saharan Africa

What is the recent experience of programs that distribute contraceptives free of charge versus for a price?

#1 #2 OR Immunity verified by immune titer (please attach report) * No titer needed if proof of two doses of Varicella provided

impact dashboard - august 2018

Measles Supplementary Immunization Activities and GAVI Funds as Catalysts for Improving Injection Safety in Africa

Status Report on WSS MDG Roadmaps and Country Status Overviews WSP Africa

Maternal Deaths Disproportionately High in Developing Countries

FP2020 Expert Advisory Community Webinar

GAVI RESOURCE GAP ALWAYS BEEN AN ISSUE

Certificate of Immunization

Gender, Poverty, and Health in Sub-Saharan Africa: A Framework for Analysis

NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL. Measles & Rubella Campaigns

Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved

Ouagadougou Declaration

POLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12

TURNING POINT FOR AFRICA AN HISTORIC OPPORTUNITY TO END AIDS AS A PUBLIC HEALTH THREAT BY 2030 AND LAUNCH A NEW ERA OF SUSTAINABILITY

Yellow fever laboratory capacity on-site assessments in Africa: preliminary findings

Children in Africa. Key statistics on child survival, protection and development

World Health organization/ International Society of Hypertension (WH0/ISH) risk prediction charts

Transcription:

COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) Sushila Maharjan Senior Manager, Innovative Finance International Conference on Sustainable Cooling World Bank Washington DC - 29 November 2018 Reach every child www.gavi.org

Gavi, the Vaccine Alliance is a public-private global health partnership Established in 2000 to address stagnating and declining immunisation rates in the poorest countries Gavi s mission: creating equal access to vaccines for all children Since inception, the Alliance has delivered real impact: keep people healthy vaccines save lives stronger economies sustainable future >700 million children immunised >10 million future deaths averted >100 billion US$ costs averted related to illness ~20 countries set to transition out of Gavi support by 2020 2

Effective vaccine cold chain is critical to achieving Gavi s immunisation goals Over 60 million children immunised every year ~1.3 billion annual investment on vaccines 15 million are still under-immunised Vaccines need to be stored within 2-8 C or they lose effectiveness Vaccine cold chain is critical to: 1) safeguard vaccine investment; and 2) increase the Alliance s vaccine coverage and equity goals 3

Up to 90% of health facilities in 55 Gavi countries either rely on outdated technologies for vaccine storage or do not have one 50% 20% 20% Equipped with older devices that may cause vaccines to freeze or be exposed to excessive heat Equipped with broken devices Unequipped with cold chain devices Lack of efficient and functioning cold chain in Gavi countries puts the Alliance s and countries investments in vaccines at high risk. 4

Improved cold chain technologies are available but their uptake by countries is slow due to two key barriers: High technology cost due to cold chain market inefficiencies, including limited demand visibility, fragmented procurement, high production cost and in-transparent pricing Lack of country financing to invest in new cold chain technologies due to the high upfront capital cost Gavi launched the Cold Chain Equipment Optimisation Platform (CCEOP) that builds demand for, and supply of, affordable and environmentally-sound new technologies to improve the effectiveness of vaccine delivery in Gavi countries 5

Responding to cold chain technology demand means meeting a country's context in a sustainable way context Technology Type On-grid facilities but with intermittent power supply Devices that have longer holdover time and keep vaccines cool and safe even if the power is intermittent or out for multiple days Off-grid facilities Dependable solar-powered devices that do not need batteries and that keep vaccines cool and temperature stable CCEOP currently focuses on two types of technologies - solar-powered solar direct drive (SDD) and energy efficient ice-lined (IL) refrigerators and freezers that meet WHO s Performance Quality and Safety standards. 6

CCEOP aims to scale-up uptake of more efficient and sustainable cold chain technologies at affordable prices Joint investment between Gavi and countries Pool technology demands from countries Pool procurement through UNICEF Equipment, deployment, service bundle and Warranty Operations & Maintenance Gavi Gavi and country coinvest between 80/20 and 50/50 depending on country s gross national income (GNI) status Eligible countries apply for funding based on their needs Gavi pools demands from approved countries UNICEF on behalf of Gavi negotiates with manufacturers for better pricing and effective deployment Manufacturers provide equipment, service bundle plus warranty (minimum of 2 years) Countries fund and implement maintenance and service during equipment operating life Through CCEOP, Gavi has committed US $250 million for a five-year period between 2017-2021 to jointly invest with countries to purchase and install equipment in about 62,000 health facilities globally. 7

CCEOP applies a preventive approach to cold chain modernisation in Gavi countries Optimal products, to better protect vaccine potency Built-in freeze protection Extended ambient temperature range (ie,10 C to 43 C) Bundled voltage stabilisers Bundled temperature monitors Cold chain equipment Service bundle, to deploy CCE more quickly, reliably and sustainably Suppliers are accountable for in-country distribution, installation, and training of end-users at facilities Ministry of Health/UNICEF or supplier is responsible for customs clearance, depending on the country situation Ice Lined Refrigerators Solar Direct Drive Manufacturer's warranty Monitoring Plan Suppliers need to provide at least 2 years of a manufacturer's warranty (some extend to 10 years) Countries need to submit a full maintenance plan with budget at the application approval stage cold boxesvaccine carrier Temp Long-term passive Monitors devices With its five-year investment, CCEOP effectively represents a $50m per year insurance policy to safeguard Gavi s ~$1.3b per year vaccine investments 8

CCEOP is already delivering results nearly halfway through its funding cycle Total eligible countries Outcome to date Out of 55 eligible countries for joint investment under CCEOP 9

But there are still challenges in implementation At the programme level: Procurement delays due to involvement of a multitude of suppliers and countries in the tender and negotiation process Rate of price reductions slower than expected At the country level: Maintaining country governments commitment to a multi-year maintenance plan. Lack of the sustained capacity needed to implement the maintenance plan (funding and technical) Consultations are ongoing with the Alliance partners to identify specific interventions to address these challenges. 10

55 countries are eligible for co-investment through CCEOP Application in process Afghanistan Bangladesh Chad DPRK Ghana Guinea-Bissau Lao People s Democratic Republic Lesotho Nigeria Sudan Tajikistan Yemen Zambia Zimbabwe Approved (ODP pending) Benin Central African Republic Ethiopia Mauritania Papua New Guinea Mozambique Procurement in process Burkina Faso Cameroon Côte d'ivoire Eritrea Gambia Kyrgyzstan Madagascar Myanmar Nepal Rwanda Senegal Solomon Islands Somalia Uzbekistan Viet Nam Deployment in process DRC Djibouti Guinea Haiti Kenya Liberia Malawi Niger Pakistan Sierra Leone South Sudan Tanzania Togo Uganda Eligible but have not applied Burundi Cambodia Comoros Mali Nicaragua São Tomé and Príncipe Syria 7

THANK YOU Reach every child www.gavi.org